Antibiotics market size will reach US$60.99 billion by 2030,


Pune, Aug. 08, 2022 (GLOBE NEWSWIRE) — The Global antibiotics market it is expected that the clock ~US$60.99 billion by 2030 due to the increasing use of antibiotics due to increased incidence of infectious and chronic diseases.

market engine

The global antibiotics market is expected to grow thanks to the increasing number of public-private partnerships, where government bodies contribute funding and cutting-edge R&D methods to companies creating antibiotics. For example, the Global Antibiotic Research and Development Partnership (GARDP) and Evotec AG announced a public-private partnership in March 2019, to create first-in-class antibiotics for the treatment of bacterial infections resistant to existing antibiotics. .

Request a sample copy of the research report:

Report Scope and Segmentation:

Report cover Details
Market size in 2021 ~$40.0 billion
Revenue forecasts in 2030 ~$60.99 billion
Rate of growth CAGR of ~4.8% from 2022 to 2030
Base year for the estimate 2021
Forecast period 2022-2030
Segments Covered Drug class, drug origin, spectrum, distribution channel
Regional scope North America, Europe, Asia-Pacific and Rest of the World (ROW)

Excerpts from ‘By segmentation by drug class’

On the basis of drug class, the global antibiotics market has been segmented into:

  • Penicillin
  • Cephalosporin
  • Aminoglycosides
  • Tetracycline
  • Macrolides
  • Fluoroquinolones
  • Sulfonamides
  • Others

The penicillin segment dominated the global market during the forecast period due to the highest prescription rate and the largest number of generic manufacturers in the market. Infections such as pharyngitis, skin infections, bronchitis, gonorrhea, and ear infections are treated with these drugs as the first line of defense. After penicillin, cephalosporins and fluroqunilones have emerged as the second largest drug class segment, and it is expected to grow significantly over the projected period due to the launch of new drugs. Three cephalosporin-based drugs are in phase III clinical trials and are expected to be marketed within three to four years. Additionally, Fetroja (cefiderocol) by Shionogi, which received US FDA approval in November 2019, is expected to increase the market share. Similarly, the acceptance by the Japanese PMDA of Lasvic (lascufloxacin) and the submission by Wockhardt Ltd. of new drug demand in India will accelerate the expansion of the fluoroquinolones market.

The emergence of COVID-19 was expected to influence the cephalosporin market as different studies compared different generations of cephalosporins to COVID-19 and found promising results. For example, in the research study “Efficacy of Ceftazidime and Cefepime in Management of COVID-19 Patients: Single Center Report from Egypt”, which was published in October 2021, it stated that the use of antibiotics for COVID-19 patients demonstrated therapeutic benefits, particularly in patients with severe pneumonia. Both ceftazidime and cefepime have shown excellent inhibitory efficacy against COVID-19, and their repurposing for symptomatic relief of patients with mild and severe COVID-19 has been determined to be highly beneficial.

Browse the full report summary with detailed table of contents:

Excerpts from ‘Segmentation by region’

On the basis of regions, the global antibiotics market has been segmented into:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

North America currently holds a dominant position in the antibiotics market and is expected to show a similar trend over the forecast period owing to the high demand and consumption of antibiotics in the region owing to the high burden of infectious diseases and the growing aging of the population. For example, according to their October 2021 update, the Centers for Disease Control and Prevention (CDC) recorded 7,174 new cases of tuberculosis (TB) in the United States in 2020. The prevalence of tuberculosis is said to be the highest among Hispanics or Latinos. , which accounted for about 30 percent of all reported TB cases in the country, according to the CDC. Thus, the emergence of new cases of tuberculosis in the country is expected to increase the need for antibiotics in the region, which is expected to fuel the expansion of the market.

Due to the high frequency and incidence of infectious diseases along with the widespread availability of antibiotics, the United States will occupy a major share of the North American antibiotics market during the forecast period. For example, according to the United Nations’ World Population Aging Highlight 2019 report, there were 53,340,000 geriatric people in the United States, 6,602,000 in Canada, and 9,462,000 in Mexico. It is predicted that by 2050, 84,813,000 people would live in the United States, 11,436,000 in Canada and 26,416,000 in Mexico.

Excerpts from “Competitive Landscape”

Some of the major players operating in the global antibiotics market include:

  • Pfizer Inc.
  • GlaxoSmithKline PLC
  • Sanofi SA
  • Abbott Laboratories Inc.
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd
  • Novartis International SA
  • Mylan AG
  • F. Hoffmann-La Roche SA
  • Allergan AG
  • Basilea Pharmaceutica Ltd
  • Nabriva Therapeutics plc
  • Among others


    1. Market ecosystem
    2. Schedule under study
      1. Historical years – 2020
      2. Base year – 2021
      3. Planned years – 2022 to 2030
    3. Currency used in the report
    1. Research approach
    2. Data collection methodology
    3. Information source
      1. Secondary sources
      2. Primary sources
    4. Market estimation approach
      1. From bottom to top
      2. From top to bottom
    5. Market Forecast Model
    6. Limits and assumptions
    1. Current market trend (COVID-19 outlook)
    2. Key players and competitive positioning (2021)
    1. Drivers
    2. Constraints
    3. Opportunities

TOC Continued.


  • Fueled by free analyst hours and expert interviews with every report
  • Comprehensive quantitative and qualitative information at segment and sub-segment level
  • Trends and perspectives of the impact of Covid 19
  • Granular information at global/regional/country level
  • In-depth insights into market dynamics (drivers, restraints, opportunities) and business environment
  • Global coverage of the competitive landscape
  • Winning imperatives
  • Comprehensive coverage of “strategic developments” recorded by major market players


  • Distributor Landscape Assessment
  • Pricing information
  • Customer evaluation
  • Analysis of investments and initiatives
  • ‘Company Profile’ of key players

Request customization of this research report to:

About Us:

Growth+Reports is part of GRG Health, a global healthcare knowledge services company. We are proud members of the EPhMRA (European Pharmaceutical Marketing Research Association).

The Growth+ portfolio of services leverages our core capabilities in secondary and primary research, market modeling and forecasting, benchmarking, analysis and strategy formulation to help clients create scalable and game-changing solutions. that prepare them for future growth and success.

We have been recognized by the prestigious CEO Magazine as “2020’s Most Innovative Healthcare Market Research Company”.


About Author

Comments are closed.